IMATINIB 800MG DAILY INDUCES DEEPER MOLECULAR RESPONSES THAN IMATINIB 400MG DAILY: RESULTS OF SWOG S0325, AN INTERGROUP RANDOMIZED PHASE II TRIAL IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA

The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukemia (CP-CML) is 400mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematologic and cytogenetic response to IM400 vs. imatinib 400mg t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Deininger, Michael W., Kopecky, Kenneth J., Radich, Jerald P., Kamel-Reid, Suzanne, Stock, Wendy, Paietta, Elisabeth, Emanuel, Peter D., Tallman, Martin, Wadleigh, Martha, Larson, Richard A., Lipton, Jeffrey H., Slovak, Marilyn L., Appelbaum, Frederick R., Druker, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127316/
https://ncbi.nlm.nih.gov/pubmed/24383843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12618
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados